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Sickle Cell Anemia:  
Current Treatments & Potential Advancements 
 
By: Vanessa Martinez 
 
 
Abstract 
 Sickle cell anemia is a disease that affects red blood cells, specifically the hemoglobin 
protein.  An amino acid mutation in the gene that encodes β-globin leads to malformation of the 
β subunit of hemoglobin.3, Valine becomes glutamic acid in the mutated β-globin gene.9 The 
mutation malformation leads to the red blood cells becoming sickle shaped, or crescent shaped.3,4 
The sickle shape of red blood cells in individuals with sickle cell disease leads to vaso-occlusive 
crisis.9 Vaso-occlusive crisis includes complications such as blood clotting, chronic pain, organ 
failure, organ death, and possibly early mortality.9 The Centers for Disease Control and 
Prevention reported that there are approximately 100,000 Americans who have sickle cell 
disease as of their August 2016 records.21 One of every 365 African-Americans, and one in every 
16,300 Hispanic-Americans have sickle cell anemia.21 There are therapies and treatments that 
have already been developed based on the knowledge gained regarding the disease and its 
complications. Currently, hydroxyurea therapy is the most widely accepted and used treatment 
for individuals with sickle cell disease with proven relief of vaso-occlusive crisis complications. 
However, with hydroxyurea therapy there are several unwanted effects that have an impact on 
the patients, such as jaundice, blood clotting, and usual bleeding just to name a few.44 Studies 
have noted an upregulation of the glycolytic enzyme, fructose-bisphosphate aldolase (aldolase) 
in patients who have undergone hydroxyurea therapy. Aldolase is an important enzyme that 
plays a role in energy conversion. With this in mind, I propose that sickle cell disease can be 
treated with an increase in aldolase by myoblast treatment and/or higher fructose consumptions 
thereby reducing the complications that come with the disease, as well as, drastically eliminating 
the unwanted effects that come with hydroxyurea therapy. 
Keywords: Sickle Cell Anemia, SCD, hemoglobin, VOC complications, aldolase, hydroxyurea 
therapy, treatments, therapy 
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CHAPTER ONE: SICKLE CELL ANEMIA 
 
Introduction 
 Sickle cell anemia (SCA), also known as sickle cell disease (SCD), is a disease that alters 
the hemoglobin in red blood cells (RBC).1 Red blood cells are commonly known to have a 
circular shape. The fact that RBCs have this shape, with other unique features, make it possible 
for them to travel throughout the body with ease.2 This flow of RBCs throughout the body is 
what allows for oxygen, iron, chemical ions, and other important nutrients to move from one 
location to another and reach their designated destination.2 In SCD, the RBC is sickled, or 
crescent shaped.3, 4 These sickled cells can lead to complications known as vaso-occlusive crisis 
(VOC), such blood clots, which can furthermore lead to tissue and/or organ failure. It was first 
brought to the attention of the United States in the early 1900s by Dr. Herrick while he was 
viewing Walter Clement Noel’s red blood cells.3, 4  Since then, there have been many contributors 
to our knowledge and understanding of SCD, including Hahn and Gillespie, Dr. Neel, Nobel 
prize winner Dr. Pauling, and Dr. Itano, just to name a few.3 
 
Background 
 Discovery. Prior to the discovery of 
sickle cell anemia in the 1900s, there was not 
enough knowledge to explain the 
manifestation of sickled cells. In 1910, Dr. 
Herrick described unusual findings in the 
blood of a young black man, of which he had 
never come across before.3 Dr. Herrick was 
very thorough writing his observations, 
describing things such as the overall physical 
features including chest deformity, redness in 
the throat, enlarged glands, and several scars 
up to 3 cm in diameter on his legs and 
thighs; enlarged left side of the heart with a 
Figure 1: Dr. Herrick's view of sickle cells4 
with added contrast for enhanced 
visualization 
		 6	
murmur and heart rate between 64 and 100; rattling in the lungs heard throughout his chest and 
back; fever that fluctuated from 99°F to 101°F; increased urine output; feces output that 
contained bloody mucus; and blood descriptions, such as the shape of the red blood cells he saw 
(figure 1).4 Herrick included the history of the young man named Walter Clement Noel including 
that he formerly lived in Grenada, West Indies4; and addressing important associated symptoms 
such as shortness of breath and palpatations3, which are defined as feeling a pounding or 
fluttering heart.4 These are common features of sickle cell anemia, however, this information was 
not known at that time. Also, Herrick noticed the distinct sickle shape of the red blood cells, 
which is the reason for the name sickle cell anemia. A vast number of Noel’s red blood cells 
were crescent-shaped, elongated, and thin.4 Dr. Herrick recognized the abnormality of the red 
blood cells remained the same in all of the blood samples, regardless of how the blood was 
smeared or treated, even after exposing the cells to heat, placing them in alcohol or ether 
solutions, and staining them with Ehrlic stain.4 Dr. Herrick, after comparison to other healthy 
individuals and looking through various aspects of Noel’s condition, could not come to a 
conclusion about what the diagnosis of the patient could be. He suggested syphilis because some 
of the symptoms seemed to be similar, however, no conclusion was made. Dr. Herrick ended his 
article with a statement about leaving the case with an open diagnosis until more cases arose with 
similar features as the young man he 
observed.4 All this to say, during that 
time period not too much was known 
about what sickle cell anemia really 
was and what caused it.  
 
 Development. Hahn and 
Gillespie in 1927 discovered what 
causes a red blood cell to sickle. The 
red blood cells are the oxygen 
transport of the body and when they 
are not carrying oxygen they form the 
crescent shape that is known as 
sickle.3 Dr. James V. Neel suspected 
Figure 2: Red blood cell hemoglobin protein depicted 
α (bottom, pink) and β (top, orange) subunits6 
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that sickle cell anemia was a hereditary disease in 1949. Following that suspicion, in 1951, Nobel 
prize-winning chemist Dr. Linus Pauling and Dr. Harvey Itano, together made the discovery of 
the chemical structure of the protein hemoglobin.3 Hemoglobin in red blood cells is a four-part 
protein. These four parts consist of two pairs that encode the two protein subunits. Those two 
pairs are the α-globin and the β-globin. Hemoglobin with its α-globin and β-globin subunits are 
shown in Figure 2.6 Dr. Pauling and Dr. Itano discovered that hemoglobin was quite different in 
those with sickle cell anemia than in healthy individuals, leading to sickle cell anemia being the 
very first disease considered a molecular disease.3 In 1956, not long after the two noted the 
chemical structure difference, Dr. Vernon Ingram determined the specific amino acid that led to 
the restructuring of hemoglobin. 
 
 Then & Now. Due to the sickling of the red blood cells, the flow of blood within the 
vascular system is very poor and can often lead to vascular restriction. Before further discoveries 
and investigations on the cause of organ tissue death, vaso-occlusion seemed to be the only 
reason these tissues died in patients with sickle cell disease. In more current findings, an overall 
interaction between red blood cells and endothelial cells, which are cells that form the lining of 
blood vessels7, plays a role in leading to dysfunction of organs. Mohandas, Hebbel, and Kaul 
were the three who prompted this concept in the 20th century. As vaso-occlusion continued to be 
studied by people such as Duits and Schnog, it became more evident that these vascular blocking 
episodes, which occurred in people with sickle cell anemia, caused the dysfunction in the organs 
differently than in healthy individuals.8, 9 Further investigation has shown a connection between 
red blood cells and blood vessel walls. It is not just the shape of the red blood cell (sickle-shape), 
but also the vessel wall adhesion, the way neutrophils are recruited and adhere to the cell wall 
causing blockage of sickled red blood cells.8, 10 
 
Genetics 
 Sickled red blood cells are noted to have only one amino acid different than normal blood 
cells.3 Figure 3 shows the genes for the α-globin and β-globin subunits of hemoglobin (discussed 
in background) and their locations on chromosomes 11 and 16, respectively.10, 11 The single 
amino acid that gets substituted is Valine, which becomes glutamic acid.10 The year Dr. Pauling 
designated sickle cell anemia as a molecular disease was the same year that it was found to 
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specifically be an autosomal 
recessive disease. The 
severity of sickle cell anemia 
is dependent on the 
interaction between the α-
globin and β-globin 
subunits.10 When the genes 
are homozygous recessive, 
sickle cell anemia is at its 
most severe and most 
common form. However, 
there are still variations of 
the disease that can occur 
based on how the genes 
interact. Usually it is the β-
globin mutation that leads to abnormal interactions and various degrees of sickle cell disease. 
When a β-globin is not produced normally, or is produced in small quantities, the gene is known 
as β-thalassemia.10 The interaction between α-globin and mutated β-globin (or β-thalassemia) 
subunits determines the severity of the disease. A normal α-globin and a mild mutation in β-
thalassemia can result in mild expression of the disease.10 Even with normal α-globin, β-
thalassemia in its inactive state resembles a recessive mutated β-globin and the severity of the 
disease is very high, similar to an individual who has have sickle cell anemia.10 
Fetal hemoglobin (HbF), with 2 γ-globin subunits, is found during fetal development and 
is replaced by adult hemoglobin (HbA), with 2 β-globin subunits, as an individual gradually 
develops into adulthood (figure 4).10, 11 Fetal hemoglobin becomes adult hemoglobin due to 
hypomethylation by the enzyme methyltransferase, which does as its name implies, transfers 
methyl groups (-CH3).12 It is not until the development of HbA and replacement of HbF is 
complete that any mutations in β-globin become more phenotypically present.11 Among some 
Eastern areas of Saudi Arabia and in some locations of India, lower rates of sickle cell disease 
were noticed coupled with higher levels of fetal hemoglobin in adults.13, 14 In another study, low 
levels of fetal hemoglobin were closely associated with increased death rates at an early age, 
Figure 3: Location of genes encoding α- globin and β-globin 
subunits of RBC hemoglobin on chromosomes 11 and 16, 
respectively.10, 11 
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50% of the 
individuals died 
before their fifth 
decade.15 These 
findings led to 
future studies in 
HbF and its 
potential in treating 
sickle cell anemia. 
 
Demographics  
 Adults. As 
studies look at 
sickle cell disease more closely, new findings lead to increased knowledge and understanding. 
Specifically, more is known about the way proteins interact within the body on a molecular level. 
Glutathione has an important part in antioxidant defense mechanisms in adults.16 Quastel, 
Stewart, and Tunnicliffe confirmed glutathione was a dipeptide of cysteine and glutamic acid17 
after the structure was originally proposed to be just that by Hopkins in 1921.18 This defense 
system is very important because it helps control and buffer the effects of reactive oxygen 
species (discussed later in chapter).19 Glutathione is now more specifically known to be 
composed of glycine, glutamate, and cysteine that come together under the catalyst glutamate 
cysteine ligase enzyme to form glutathione (figure 5).16, 20 The intermediate of this reaction is γ-
Figure 5: Structural formula (left) and ball-and-stick model (right) of glutathione20 	
Figure 4: Fetal hemoglobin with 2 γ-globin subunits (top hemoglobin) 
before development and replacement to 2 β-globin subunits in adult 
hemoglobin (bottom hemoglobin)10, 11 
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L-glutamyl-L-cysteine, which is also the rate-limiting-step in the synthesis of glutathione. On the 
other hand, another reaction that can lead to the synthesis of glutathione is from a glutathione 
disulfide by glutathione reductase enzyme. Glutathione is considered to be considerably low in 
those who have sickle cell anemia, but the reason as to why or how the deficiency occurs is not 
fully known. There seem to be factors, based on studies, that lack of sulfur amino acids 
consumed in one’s diet can have an influence on the lack of glutathione that is produced.16 
Another possible explanation is because individuals with sickle cell anemia have such high 
oxidative stress within their bodies, then glutathione produced gets used by the body so quickly 
that red blood cell count decreases because of the consumption. The latter seems to be what is 
occurring on the molecular lever.16 
 
 African Decent. In 1910 when sickle cell anemia was first discovered in the United 
States, the first view of sickle cells was in a young black man from the Grenada Islands in the 
West Indies.5  Furthermore, sickle cell anemia has been known by other names in Africa for over 
five thousand years.4 Yet, it was not until the early 1900s when the disease started to become 
more clearly understood. There is commonality of the disease mostly in those from African 
descent. In Jamaica, there are increased occurrences of homozygous βs disease, which is a type 
of sickle hemoglobin disease.21 If the homozygous mutation of β-globin is not present, an 
individual can still be considered a carrier of sickle cell disease due to the presence of mild 
mutation in the gene. This particular presence of a mild mutation that does not lead to sickle cell 
disease is known as having sickle cell trait.22 In many areas of Africa where malaria disease is 
highly prevalent, individuals with sickle cell trait were also more prevalent and seemed to 
strive.22 Malaria is a disease that causes rupturing of red blood cells due to infection of 
parasites.23 Individuals with sickle cell trait, who do not have sickle cell disease, have lower 
susceptibility to contracting malaria, however, the mechanism by which this occurs is not 
understood.24 Although being a carrier of sickle cell trait can be beneficial against malaria, when 
individuals who carry the sickle cell trait in these areas reproduce, their children are more likely 
to be born with the homozygous recessive sickle cell disease and all of its complications. 
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 World Health Organization published data regarding the prevalence of sickle cell anemia 
among various regions of the world in 2003 (Table 1).25 At that time, it was once again 
confirmed that individuals of African decent have higher percentage of having sickle cell 
anemia.21 The table shown also indicates that those of African descent also have higher amount 
of births affected by sickle cell anemia that those in any other region of the world.25  
According to the Centers for Disease Control and Prevention (CDC) August 2016 
records, there are approximately 100,000 Americans who have SCD. Out of 365 African-
Americans, one will have the disease. Out of every 16,300 Hispanic-Americans births, one will 
be diagnosed with SCD. Sickle cell trait is carried in one out of 13 African-Americans.26 This 
Table 1: WHO table showing the prevalence of sickle cell anemia among various regions of 
the world in 2003. Significant variant refers to sickle cell trait in which the individual 
carries the gene but does not physically show symptoms, and α thalassaemia refers to the 
other mild mutations that can take place. African regions have a higher percent of 
individuals who are carriers of the gene over any other region. There is a much higher 
affected popluation in African regions who have sickle cell anemia, 10.86 per 1,000. The 
number of births affected are also much higher in African regions.25  
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increases the chances of carrier parents to have offspring with sickle cell disease. Women with 
sickle cell disease lived o be 42 years old in 2005. Men with sickle cell disease only lived to be 
about 38 years old.27 
 
Complications 
Cardiovascular. 
In regards to the 
complications that sickle 
cell disease bears, its 
affect on one’s 
cardiovascular system is 
obviously one of the most 
prominent. Due to the 
fact that sickle cell 
anemia is literally a 
disease of red blood cells 
makes this very evident. 
Furthermore, VOC can 
result in acute or chronic 
pain, blood clotting, 
organ failure, organ 
death, and early 
mortality.10 The 
termination of blood flow due to clotting (figure 6), the lack of oxygen transport, and cell-vessel 
adhesion interactions, all play a role in these VOCs.10 There is evidence that supports xanthine 
oxidase is a reactive oxygen species that plays a significant role in individuals with sickle cell 
anemia.28 An increase of xanthine oxidase is usually evident in the endothelium of the aorta, or is 
possibly released from the liver and travels through blood vessels. Further investigations need to 
be performed to come to a better understanding of the effects xanthine oxidase has on tissues of 
the body, especially because not all tissues are affected in the same way.28  
 
Figure 6: Blood clotting, vaso-occlusive crisis10 
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Neurological. Reactive oxygen species are reduced oxygen molecules with added 
electrons.29 Typically, reactive oxygen species are regulated by anti-oxidant enzymes within 
individuals to ensure that one does not get harmed by inconsistencies. When these are not 
regulated properly, cells begin 
to dysfunction and die. Some 
of the molecules that have a 
role in producing reactive 
oxygen species include 
xanthine oxidase, NADPH 
oxidase, cyclo-oxygenase, 
hydroxyl radical, nitric oxide 
synthase (NOS), and 
lipoxygenase (examples 
shown in figure 7).28, 29 Nitric 
oxide synthase is the enzyme 
that catalyzes the 2-step 
production of nitric oxide 
from a L-arginine to L-citrulline reaction.29 Nitric oxide synthase is a reactive oxygen species 
that has an affect on individuals with sickle cell anemia. Normally, NOS produces small amounts 
of nitric oxide, which is used in neurons for the cascade that leads to neural transmission and 
relaxation of vessels, which inhibits aggregation of platelets.30 Nitric oxide has several 
pathological effects that are toxic to neurons, but are not fully understood.31, 32 Among some of 
the toxic effects are energy depletion and neuron death, both of which are not fully detailed or 
explained.33 More research is desired specifically in neural complications of sickle cell anemia 
because not too much information is known about the details of these kinds of complications.  
 
 
 
 
 
 
Figure 7: Examples of some reactive oxygen species29 
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CHAPTER TWO: CURRENT TREATMENTS 
 
Introduction 
 There is currently no cure for sickle cell anemia because there is still more to learn about 
the disease. Currently, only treatments are offered to ease the complications of sickle cell 
anemia. Animal studies have been conducted to determine the role of reactive oxygen species, 
endothelium adhesion, and the role of fetal hemoglobin. To date, hydroxyurea therapy is the 
treatment most used and accepted for individuals with sickle cell anemia.28 And still, research is 
being done on treatments that can improve the quality of life for those with the disease, as well 
as, treatments that ease the complications without leading to other unwanted affects. 
 
Animal Studies 
There is evidence that reactive oxygen species play a role in individuals with sickle cell 
anemia. When comparing anti-oxidant levels in normal red blood cell individuals and sickle 
blood cell individuals, there is a notable difference that can be investigated.28 A study was done 
by Kaul et al in 2004 on transgenic mice with sickle cell anemia looking at and measuring the 
reactive oxygen species in mice with induced hypoxic crises.34 Both xanthine oxidase and 
nitrotyrosine deposition are reactive oxygen species known to increase in mice with sickle cell 
anemia.34 Inflammation responses in the mice were determined to be induced by nuclear factor-
κB (NF-κB).34, 35 NF-κB is a transcription factor that increases the transcription of endothelial 
cell adhesion molecules, which are molecules that are pro-inflammatory.35 The activation of this 
particular transcription factor plays a role in increased neutrophil recruitment, which was seen in 
figure 5 to lead to vaso-occlusive crisis.36, 10 Kaul et al. specifically studied sulfasalazine and its 
ability to treat the vaso-occlusive crisis in the transgenic sickle cell disease mice.34 Sulfasalazine 
is an inhibitory agent that inactivates NF-κB in rheumatoid arthritis and inflammatory bowl 
disease.37, 38 With this in mind for their study, Kaul et al. determined that sulfasalazine did 
decrease neutrophil recruitment and adhesion, thus allowing for better vascular blood flow; 
ultimately, being an effective anti-inflammatory drug.34 By increasing reactive oxygen species 
inhibitors or anti-oxidant enzymes, artery dilations tend to be reduced and the leucocyte count 
decreases as well.28 This suggests that reversing ROS is possible and can reduce vaso-occlusive 
crises.  
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Anemic baboons were used to test out the effects of 5-Azacytidine on fetal hemoglobin 
production.39 5-Azacytidine is a cytosine analog that cannot be methylated by a 
methyltransferase.39 This molecule was used to inhibit the methylation of DNA that encodes for 
β-globin. Since 5-Azacytidine inhibited this methylation, a higher number of fetal hemoglobin 
was expressed in the baboons than adult hemoglobin expressed.39 This was used as a push 
towards getting 5-Azacytidine tested on humans,39 however, it was not studied further due to the 
fact it was thought to be carcinogenic.10 Studies were then done on hydroxyurea therapy because 
it does not interfere with the methyltransferase of DNA.28, 39 This encouraged small hydroxyurea 
trials on humans. Unlike 5-Azacytidine, hydroxyurea became tested on larger sample sizes to get 
more understanding of its effect on sickle cell anemic organisms.10 Because of these studies, 
hydroxyurea therapy has become the most utilized therapy for SCD patients. 
  
Hydroxyurea Therapy  
 Hydoxyurea is a drug that has been approved by the US Food and Drug Administration 
that can be used as a 
therapy for sickle cell 
anemia.28 This drug 
therapy can 
effectively reduce 
sickle cell anemia 
symptoms such as 
vaso-occlusion, 
pulmonary events, and 
hospital visits, to 
name a few.10, 28, 39, 40 
The function of 
hydroxyurea therapy 
can be visualized in 
figure 8.41 One of the 
mechanisms of HU 
induces the fetal 
Figure 8: What hydroxyurea affects41 although the mechanism is not 
known  
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hemoglobin (HbF) synthesis in SCD patients. This synthesis impairs the production of sickle cell 
formation, thus extensively reducing the VOC complications.41 It was in 1984 when Letvin et al. 
studied anemic monkeys and HU therapy, determining the increased production of HgF.42 
Several VOCs are treated when patients undergo HU therapy. This therapy does not actually get 
rid of sickle cell anemia entirely, it just helps reduce the complications that come with the 
disease.10 In regards to humans, symptoms like acute chest pain, hospitalizations, painful crises, 
and blood transfusions greatly declined when patients were on hydroxyurea therapy. 43 However, 
it is important to note that the exact mechanism HU therapy uses is unknown. Patients who have 
gone through HU therapy have experienced several unwanted effects. Some of those unwanted 
effects include, but are not limited to, body aches, flu-like symptoms, easy bruising, unusual 
bleeding, painful or difficult urination, confusion, hallucinations, loss of appetite, nausea, and 
jaundice.44 
 
Other Therapies 
 It has been proposed to induce fetal hemoglobin in individuals with sickle cell anemia to 
alleviate the severity of the disease. There have been studies and observations that lead to this 
therapeutic proposal. Individuals with sickle cell anemia in India and Saudi Arabia have high 
amounts of fetal hemoglobin and much milder sickling. Also, fetal hemoglobin seems to prevent 
sickle hemoglobin from polymerizing and causing red blood cells to sickle. Therefore, induction 
of fetal hemoglobin may be a useful therapy to look further into.10 Prior to simply inducing fetal 
hemoglobin, it was suggested to use 5-Azacytidine because in a small number of sickle cell 
anemic patients it promoted fetal hemoglobin. Yet, bigger sample sizes were not sought after to 
continue testing out this method of producing fetal hemoglobin because it was a potential 
carcinogen.10 
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CHAPTER THREE: ALDOLASE, POTENTIAL TREATMENT 
 
Introduction 
 Currently hydroxyurea therapy is the most used and accepted treatment for individuals 
with sickle cell anemia.28 This therapy is used because it helps to reduce the complications that 
arise with sickle cell anemia, such as blood clotting, organ failure, and early mortality.10, 28, 39, 40 
Individuals with sickle cell anemia who undergo hydroxyurea therapy have less chest pain, 
hospital visits, blood transfusions, and painful vascular cirses.41 Sickle cell formation is inhibited 
due to increased production of fetal hemoglobin.41 Although hydroxyurea is used for treatment, it 
is not a means of curing sickle cell disease.10 The mechanism by which hydroxyurea functions is 
not known and it has several unwanted affects that it is accompanied with, such as jaundice, 
confusion, loss of appetite, nausea, hallucinations, and unusual bleeding just to name a few.43 
After doing some research, aldolase has been found in higher amounts in individuals with sickle 
cell anemia who undergo hydroxyurea therapy.45 Due to this finding, the proposal to increase 
aldolase by another means is presented. Increasing aldolase without the use of hydroxyurea 
therapy can both improve the quality 
of life for individuals with sickle cell 
anemia, as well as, rid the unwanted 
affects that accompany the treatment. 
 
Background 
Fructose-bisphosphate (FBP)  
aldolase is a glycosomal enzyme that 
plays a major role in glycolysis. This 
enzyme can be found in three 
isozymic forms, defined as various 
forms with the same function, 
depending on the location of where it 
is found. Those three forms are 
aldolase A, aldolase B, and aldolase Figure 9: 2-dimensional structure of Fructose-
bisphosphate aldolase49 
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C. Aldolase A is most commonly found in muscle cells. Aldolase B is most commonly found in 
liver cells. Lastly, aldolase C is most commonly found in the brain.46, 47 Studies have shown that 
the structure of aldolase is an α/β-barrel fold.48 The structure of aldolase is shown in figure 9.49 
The glycolytic function synthesizes ATP, which is the energy that can be used for more 
biological processes.50 Aldolase A is defined based on its abundance in muscle tissues and its 
high catalytic activity. Aldolase B is defined based on the properties it has in the liver tissue and 
its low catalytic activity.51 Because aldolase is found in the cytoplasm of cells and it is soluble, 
then it can be extracted by a water solution and isolated for further study.52 
Studies have shown that there are increases in aldolase levels in patients who have 
undergone HU therapy.45 These studies form the basis of my senior capstone proposal. From 
these studies I have formed my capstone on studying a way to increase aldolase by another 
means, and replace HU therapy so the patients no longer experience the unwanted effects of the 
treatment. 
 
Research Strategy 
Specific Aim 1: To investigate the role aldolase plays in treatment of SCD in patients who 
undergo HU. 
 
Rationale: Studies have shown that aldolase levels increase in patients who have 
undergone HU therapy.45 
  
 Approach 1: The initial step is 
to measure the levels of aldolase in test 
subjects to confirm the increase of 
aldolase in my test subjects. My control 
group will consist of 20 transgenic 
mice expressing human α and βs 
globins that do not undergo HU 
therapy. The test group will be 20 adult 
transgenic mice expressing human α 
and βs globins that undergo HU Figure 10: Example of electrophoresis50 
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therapy. Blood samples will be taken and electrophoresis will be done to check the aldolase 
levels in each mouse. Figure 10 is an example of electrophoresis done to measure the enzyme 
aldolase.50 
 
 Proposed Results: I expect to see higher levels of aldolase in the test group of transgenic 
mice expressing human α and βs globins that undergo HU therapy.  
 
Conclusion: Aldolase is present in higher amounts in SCD mice, which may indicate its 
importance in SCD treatment. 
 
Approach II: The next part of the approach to investigating specific aim 1 is to knock 
down aldolase in mice that undergo HU therapy by transfection of cells with siRNA. 
Transfection means to infect with a free nucleic acid. siRNA is considered the silencing ribose 
nucleic acid. Through this method aldolase is knocked down in the transgenic mouse.53 My 
control group will consist of 20 transgenic mice expressing human α and βs globins that do not 
do not have aldolase blocked. The test group will be 20 adult transgenic mice expressing human 
α and βs globins that do have aldolase blocked. Blood samples will be taken and electrophoresis 
will be done to check the aldolase levels in each mouse. Sickle cell disease complications will be 
measured and compared. The way to measure these complications is to note the complications 
that each mouse encounters. There is a successful measurement when complications have been 
reduced. 
 
Proposed Results: I expect to see a greater reduction in sickle cell disease complications 
in the control group of transgenic mice expressing human α and βs globins that do not have 
aldolase blocked.  
 
Conclusion: SCD complications will significantly decrease in the transgenic mice 
expressing human α and βs globins that do not have the aldolase blocked. This will reinforce that 
aldolase does indeed play a key role in the treatment of sickle cell disease. 
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Specific Aim 2: To investigate an alternative method for increasing aldolase without using 
hydroxyurea to eliminate unwanted effects. 
 
Rationale: HU therapy has unwanted effects for patients.44 
 
Approach I: Measure the improvement of SCD complications by increasing aldolase 
through the means of myoblasts. A study was done revealing that aldolase levels increased due to 
myoblasts. Myoblasts are muscle cells. This can be done by getting the mice to exercise thereby 
encouraging the formation of myoblast and increasing aldolase levels. My control group will 
consist of 20 transgenic mice expressing human α and βs globins that do not do not undergo the 
myoblast treatment. The treatment group will be 20 adult transgenic mice expressing human α 
and βs globins that do undergo the myoblast. Blood samples will be taken and electrophoresis 
will be done to confirm the increased aldolase levels in each mouse. Sickle cell disease 
complications will be measured and compared. The way to measure these complications is to 
note the complications that each mouse encounters. There is a successful measurement when 
complications have been reduced. 
 
Proposed Results: The treatment group with 20 transgenic mice expressing human α and 
βs globins that do undergo the myoblast treatment will have increased levels of aldolase and 
show significant reduction of sickle cell disease complications. 
 
Conclusion: Increasing aldolase by myoblast treatment will reduce sickle cell disease 
complications and eliminate the need for HU therapy and unwanted effects. 
 
Approach II: The second part of the approach to investigating specific aim 2 is to 
measure the improvement of sickle cell disease complications by increasing aldolase through the 
means of higher fructose consumption. A study was done showing that rats have increased levels 
of aldolase when consuming higher amounts of fructose.54 Figure 11 shows the results of higher 
aldolase levels in rats that consumed higher amounts of fructose.54 My control group will consist 
of 20 transgenic mice expressing human α and βs globins that consume the normal chow. The 
test group will be 20 adult transgenic mice expressing human α and βs globins that consume 
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chow with 60% fructose. 
Blood samples will be taken 
and electrophoresis will be 
done to check the aldolase 
levels in each mouse. Sickle 
cell disease complications 
will be measured and 
compared. The way to 
measure these complications 
is to note the complications 
that each mouse encounters. 
There is a successful measurement when complications have been reduced. 
 
Proposed Results: The treatment group with 20 transgenic mice expressing human α and 
βs globins that do consume more fructose will have increased levels of aldolase and show 
significant reduction of sickle cell disease complications.  
 
Conclusion: Increasing aldolase by higher fructose consumption will reduce sickle cell 
disease complications and eliminate the need for HU therapy and unwanted effects. 
 
Study Limitations 
  Some limitations of the study is that, even though we know aldolase increases in 
patients who undergo HU therapy, we are not guaranteed that aldolase is specifically the 
mechanism that HU therapy works by. Also, we do not know the other unwanted effects that 
may come with the proposed alternative methods that will increase aldolase. It is uncertain what 
the myoblast treatment or the higher fructose consumption may do to the patient. Furthermore, 
because we do not know the acute effects that may come along with these methods, we also do 
not know their long-term effects either. 
 
 
 
Figure 11: Results indicating higher aldolase levels in rats 
that consumed higher amounts of fructose54 
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Significance of Study 
  The significance of this particular study I am proposing is finding the mechanism 
that HU therapy uses to treat sickle cell disease. If this proposed study and expected results do 
indeed indicate that increased levels of aldolase is the key in treatment of the disease in mice 
models, then we are able to move to the next step of testing. Human patients can be recruited to 
attempt these treatments and see the effectiveness they have on sickle cell disease complications. 
This study will have eliminated the unwanted effects of HU therapy and helped improve patients 
lives. 
 
 Future Studies 
  A future study can be done to investigate the limitations mentioned above. In the 
future, the effects of the myoblasts treatment and high fructose consumption treatments can be 
studied and monitored. In addition to investigating the effects, a study can be done looking into a 
variety of dosages of the treatments. For example, instead of 60% fructose studying 80% or 50%. 
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DISCUSSION 
 As time and technology progress more becomes known about sickle cell anemia and the 
various factors that are involved in the disease. After the initial discovery of the disease in the 
United States in the 1900 by Dr. Herrick, much has been discovered about the effects of sickle 
cell anemia.3 Not too long after its discovery, Dr. Vernon found the amino acid that caused the 
abnormality in the β-globin gene, which leads to the sickling of a red blood cell.3 Along the years 
research has been done, and continues to be done, searching for a therapy or treatment for this 
cardiovascular disease. Symptoms such as, organ dysfunction, hospitalization, vaso-occlusion, 
and some others are the crisis that patients with sickle cell disease must deal with.10 Fortunately, 
with the information that has been gained over the years about how sickling happens and how 
anemia affects the body, treatments and therapies are being tested. Hydroxyurea is among the 
most accepted therapies currently available with significant lessening of the complications and 
symptoms sickle cell anemia patients’ have.10, 28 Further studies and investigations are being 
done on other procedures and drugs that can possibly help alleviate the difficulties of this 
hereditary disease.3 
 There is still so much to learn and investigate in regards to sickle cell anemia. Most of all, 
beginning to view the organic chemistry behind the disease will help know how to directly 
interact with molecules in a way to provide treatment. Reading through the information that is 
already present and understanding the way that molecular interactions take place, or even being 
able to see how organic chemistry plays a role in sickle cell anemia can provide a unique 
perspective on further studies and therapies. Mutations, molecular interactions, oxygen-based 
reductions, electrons, and so much more, allow for treatments and therapies to be specifically 
aimed at providing health and comfort even with sickle cell anemia. Treatments and therapies are 
already present, but still can be further investigated. Hydroxyurea is currently a favored therapy 
with unwanted and unhealthy affects, but that is not to negate that there may be other options or 
forms of treatment that might just be better. It simply is a matter of knowing what to look for, 
knowing the molecular connections and interactions involved, addressing specific areas by 
taking note of the chemistry of the molecules involved, etc. For this reason, I researched and 
propose that Fructose-bisphosphate (FBP) aldolase is a better, less harming approach to treating 
sickle cell anemia. Studies have already shown the increase of aldolase levels in patients who 
undergo hydroxyurea therapy, but studies also show the unwanted affects that go alongside the 
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treatment.44, 52 For example, jaundice, loss of appetite, body aches, and unusual bleeding, just to 
name a few, are some the complications that patients who undergo HU therapy must suffer 
through in order to alleviate VOC complications that come with SCD.44 If an increase in aldolase 
is the mechanism by which the VOC symptoms are being relieved, then increasing aldolase by 
another means rather than HU therapy will help remove these unwanted affects of the therapy. 
Although aldolase cannot be a cure for SCD, based on my research, increasing aldolase can 
improve the overall health and condition of those who live with sickle cell anemia. 
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